Ultragenyx UK

Company snapshot

Ultragenyx UK maintains 201 tracked programs across Cystic Fibrosis, Multiple Sclerosis, Fanconi's Anemia, Hereditary Inclusion Body Myopathy, Systemic Lupus Erythematosus, Systemic Sclerosis, Osteogenesis Imperfecta, Rett Syndrome, Tourette Syndrome, GNE Myopathy, Hemophilia B, Pain. Momentum score: 20/100 (30-day delta: n/a). Public registry data covers pipeline phase, clinical trials, patents,

• 4 approved product(s) across US/EU regulatory metadata.
• 201 active pipeline program(s) linked via ClinicalTrials.gov.
• 23 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Ultragenyx UK. Not investment advice.

• Peer + 0 momentum

  Teva Pharma

  TA overlap score 40

• Peer + 0 momentum

  Vertex Pharmaceuticals (Australia)

  TA overlap score 40

• Peer + 0 momentum

  Novartis India

  TA overlap score 40

• Peer + 0 momentum

  Jazz Pharmaceuticals Ireland

  TA overlap score 40

• Peer + 0 momentum

  Lakefront Biotherapeutics NV

  TA overlap score 39.8

• Peer + 0 momentum

  Kyverna Therapeutics

  TA overlap score 22.8

• Peer + 0 momentum

  Corbus Pharmaceuticals

  TA overlap score 22.2

Recent activity

Latest pipeline, patent, and corporate events for Ultragenyx UK.

1. Jun 8, 2026 Clinical update

   2015-1949 — Phase 3

2. Jun 8, 2026 Clinical update

   AS/BW/ENE-21/0003 — Phase 1

3. Jun 8, 2026 Clinical update

   whole-cell pertussis vaccine — Phase 3

4. Jun 8, 2026 Clinical update

   von Willebrand factor — Phase 1

5. Jun 8, 2026 Clinical update

   UX053 — Phase 2

View all clinical trial activity →

• What is Ultragenyx UK?

  UGenDx is a pharma organization headquartered in NOVATO, CA, GB. It trades on NYSE under ticker RARE. Primary therapeutic focus areas include Cystic Fibrosis, Multiple Sclerosis, Fanconi's Anemia, Hereditary Inclusion Body Myopathy, Systemic Lupus Erythematosus. NovaPharmaNews li

• Is Ultragenyx UK publicly traded?

  Yes. Ultragenyx UK is listed with ticker RARE on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Ultragenyx UK develop or market?

  We link 168 drug profile(s) where Ultragenyx UK is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ultragenyx-pharmaceutical#company-drugs.

• What are the latest developments for Ultragenyx UK?

  In the last 12 months our linked public records show 201 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does Ultragenyx UK focus on?

  Ultragenyx UK focuses on Cystic Fibrosis, Multiple Sclerosis, Fanconi's Anemia based on our analysis of their pipeline programs and drug development activities.